These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

329 related articles for article (PubMed ID: 8308273)

  • 1. Large-scale expansion in interleukin-2 of tumor-infiltrating lymphocytes from patients with ovarian carcinoma for adoptive immunotherapy.
    Freedman RS; Tomasovic B; Templin S; Atkinson EN; Kudelka A; Edwards CL; Platsoucas CD
    J Immunol Methods; 1994 Jan; 167(1-2):145-60. PubMed ID: 8308273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor-infiltrating lymphocytes and low-dose recombinant interleukin-2: a pilot trial.
    Freedman RS; Edwards CL; Kavanagh JJ; Kudelka AP; Katz RL; Carrasco CH; Atkinson EN; Scott W; Tomasovic B; Templin S
    J Immunother Emphasis Tumor Immunol; 1994 Oct; 16(3):198-210. PubMed ID: 7834119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS; Kudelka AP; Kavanagh JJ; Verschraegen C; Edwards CL; Nash M; Levy L; Atkinson EN; Zhang HZ; Melichar B; Patenia R; Templin S; Scott W; Platsoucas CD
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transduction of rIL-2 expanded CD4+ and CD8+ ovarian TIL-derived T cell lines with the G1Na (neor) replication-deficient retroviral vector.
    Nash MA; Platsoucas CD; Wong BY; Wong PM; Cottler-Fox M; Otto E; Freedman RS
    Hum Gene Ther; 1995 Nov; 6(11):1379-89. PubMed ID: 8573611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer.
    Schiltz PM; Beutel LD; Nayak SK; Dillman RO
    J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cytolysis by lymphocytes infiltrating ovarian malignant ascites.
    Ioannides CG; Platsoucas CD; Rashed S; Wharton JT; Edwards CL; Freedman RS
    Cancer Res; 1991 Aug; 51(16):4257-65. PubMed ID: 1868446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
    Kooi S; Zhang HZ; Patenia R; Edwards CL; Platsoucas CD; Freedman RS
    Cell Immunol; 1996 Dec; 174(2):116-28. PubMed ID: 8954611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC.
    Hayakawa K; Salmeron MA; Parkinson DR; Markowitz AB; von Eschenbach AC; Legha SS; Balch CM; Ross MI; Augustus LB; Itoh K
    J Immunother (1991); 1991 Oct; 10(5):313-25. PubMed ID: 1790139
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of human tumor-infiltrating lymphocytes expanded in hollow-fiber bioreactors for immunotherapy of cancer.
    Malone CC; Schiltz PM; Mackintosh AD; Beutel LD; Heinemann FS; Dillman RO
    Cancer Biother Radiopharm; 2001 Oct; 16(5):381-90. PubMed ID: 11776755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy for peritoneal ovarian carcinoma metastasis using ex vivo expanded tumor infiltrating lymphocytes.
    Freedman RS; Platsoucas CD
    Cancer Treat Res; 1996; 82():115-46. PubMed ID: 8849947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma.
    Apiranthitou-Drogari M; Paganin C; Bernasconi S; Losa G; Maneo A; Colombo N; Mantovani A; Allavena P
    Cancer Immunol Immunother; 1992; 35(4):289-95. PubMed ID: 1387344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
    Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphocytes infiltrating ovarian malignant ascites: modulation of IL-2-induced proliferation by IL-4 and of selective increase in CD8+ T cells by TNF-alpha.
    Ioannides CG; Rashed S; Fisk B; Fan D; Itoh K; Freedman RS
    Lymphokine Cytokine Res; 1991 Aug; 10(4):307-15. PubMed ID: 1932375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific antitumor activity of tumor-infiltrating lymphocytes expanded first in a culture with both anti-CD3 monoclonal antibody and activated B cells and then in a culture with interleukin-2.
    Tamada K; Harada M; Okamoto T; Takenoyama M; Ito O; Matsuzaki G; Nomoto K
    Cancer Immunol Immunother; 1995 Dec; 41(6):339-47. PubMed ID: 8635191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of fresh (uncultured) tumour-infiltrating lymphocytes (TIL) and TIL-derived T cell lines from patients with renal cell carcinoma.
    Mitropoulos D; Kooi S; Rodriguez-Villanueva J; Platsoucas CD
    Clin Exp Immunol; 1994 Aug; 97(2):321-7. PubMed ID: 8050183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant interleukin-2-expanded tumor infiltrating lymphocytes from human renal cell cancer do not exhibit autologous tumor cell-specific cytotoxicity.
    Nishimura T; Terashima Y; Hattori T; Satoh M; Kondo Y; Kimura G; Yoshida K; Akimoto M
    Urol Int; 1991; 47 Suppl 1():83-5. PubMed ID: 1949387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Large scale expansion of human tumor infiltrating lymphocytes with surface-modified stimulator cells for adoptive immunotherapy.
    Chin Y; Janssens J; Smeyers E; Bleus J; Zhang J; Raus J
    Anticancer Res; 1992; 12(3):733-6. PubMed ID: 1622131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.